In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
News|Podcasts|June 4, 2026
ACT Brief: AI-Driven Enrollment Results, Statistician Standards in Early Phase, and RNA Editing for Kidney Disease
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine AI-enabled site performance in a Sanofi COPD study, why statisticians raising early phase standards matters to the entire development pathway, and a new partnership on RNA exon editing for monogenic kidney disease.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- In part two of her post-SCOPE X
interview , Liz Beatty shared results from a Sanofi COPD study where AI-enabled sites screened patients 33% faster and achieved 100% enrollment success, including reviving a site that had been non-performing for over 100 days. The data demonstrates how precise patient matching and operational guidance translates into measurable enrollment acceleration. - In a new
Q&A building off her recent video interview, Sam Hinsley of Phastar discussed why statisticians raising standards across the development timeline is critical, particularly in early phase where foundation decisions determine entire program success. Hinsley highlighted the newly launched Early Phase ESIG, bringing together statisticians from academia and industry to share knowledge and advance approaches for complex diseases requiring innovative design methodologies. - Ascidian Therapeutics and Eli Lilly entered a
collaboration on RNA exon editing for monogenic kidney diseases, with Ascidian eligible to receive up to $1.9 billion in milestone payments. The platform addresses kidney disease genetics previously difficult to treat, with option to expand to additional disease targets.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today’s ACT Brief, we examine how AI is moving into continuous clinical operating models, how trust is built into oncology real-world evidence, and how the FDA approved a self-administered option for thyroid eye disease.
In today’s ACT Brief, we examine who decides what trials measure, how designing for human thinking improves site execution, and how the FDA extended an immunotherapy to a new bladder cancer population.
In Episode 3 of The Human Side of Clinical Trials, hosts Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., speak with Jason Riis, PhD, CEO and chief behavioral scientist at Behavioralize, about why a well-written protocol doesn’t always translate into consistent execution, and how designing for the way people actually think and learn can reduce site burden and the need for costly unlearning.
In today’s ACT Brief, we examine what it will take to scale EHR-to-EDC connections for real-time trials, how the FDA is reimagining rare disease drug development, and why oncology real-world evidence still faces persistent data barriers.
In today's ACT Brief, we examine how representation gaps in trials are shaped by structural design decisions, how new partnerships automate data transfer from site systems to sponsor platforms, and how Roche is licensing a novel obesity target from a biotech pioneer.
Aardvark released exploratory data from its stopped Phase 3 HERO trial in Prader-Willi syndrome after FDA lifted the hold, and plans a redesigned Phase 3.
Clinical trials capture data faster than ever, but the real bottleneck is the distance between data capture and a decision teams can trust.
Trending on Applied Clinical Trials Online
1
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
2
Bipartisan Bill Would Build Reusable Clinical Trial Networks, With a Focus on Rare Disease
3
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
4
ACT Brief: Orchestrated AI Clinical Environments, eSource Coordinator Satisfaction, and Faster Clinical Trials Act
5